H S Dafsari1,2, K Ray-Chaudhuri2, P Mahlstedt1, L Sachse1, J K Steffen1, J N Petry-Schmelzer1, T A Dembek1, P Reker1, M T Barbe1, V Visser-Vandewalle3, G R Fink1,4, L Timmermann1,5. 1. Department of Neurology, University Hospital Cologne, Cologne, Germany. 2. National Parkinson Foundation Centre of Excellence, King's College Hospital, London, UK. 3. Department of Stereotaxy and Functional Neurosurgery, University Hospital Cologne, Cologne. 4. Cognitive Neuroscience Institute of Neuroscience and Medicine (INM-3), Research Centre Jülich, Jülich, Germany. 5. Department of Neurology, University Hospital Giessen and Marburg, Campus Marburg, Germany.
Abstract
BACKGROUND AND PURPOSE: Subthalamic nucleus (STN) deep brain stimulation (DBS) improves quality of life (QoL) and motor and non-motor symptoms in advanced Parkinson's disease (PD). However, its effect on alexithymia and its relationship to other neuropsychiatric symptoms and QoL in PD is unclear. METHODS: In this prospective, observational study of 39 patients with PD undergoing STN-DBS, we examined the Parkinson's Disease Questionnaire-8 (PDQ-8), 20-item Toronto Alexithymia Scale (TAS-20), Hospital Anxiety and Depression Scale (HADS), Self-Report Manic Inventory (SRMI), Apathy Evaluation Scale (AES), Unified Parkinson's Disease Rating Scale (UPDRS) activities of daily living, UPDRS motor examination and UPDRS complications (UPDRS-II/-III/-IV) and levodopa-equivalent daily dose (LEDD) pre-operatively and at 5-month follow-up. Outcome changes were tested with Wilcoxon signed-rank or paired t-test when parametric tests were applicable and corrected for multiple comparisons. The relationship between outcome changes was explored with bivariate correlations. Additionally, partial correlations between PDQ-8 and TAS-20 were computed controlling for HADS, SRMI and AES change scores. Predictor analyses for PDQ-8 improvement were calculated for all baseline parameters. RESULTS: The baseline prevalence of alexithymia was 17.9%. We observed significant beneficial effects of STN-DBS on PDQ-8, TAS-20, HADS, UPDRS-II, -III and -IV scores and significant LEDD reduction. The correlation between TAS-20 and PDQ-8 improvements remained significant after controlling for all other aforementioned outcomes. Predictor analyses for PDQ-8 improvement were significant for PDQ-8 and TAS-20. CONCLUSIONS: This is the first report of beneficial effects of STN-DBS on alexithymia. Alexithymia was significantly associated with QoL outcome independent of anxiety, depression, mania and apathy. Our study highlights the importance of alexithymia for holistic assessments of DBS outcomes.
BACKGROUND AND PURPOSE: Subthalamic nucleus (STN) deep brain stimulation (DBS) improves quality of life (QoL) and motor and non-motor symptoms in advanced Parkinson's disease (PD). However, its effect on alexithymia and its relationship to other neuropsychiatric symptoms and QoL in PD is unclear. METHODS: In this prospective, observational study of 39 patients with PD undergoing STN-DBS, we examined the Parkinson's Disease Questionnaire-8 (PDQ-8), 20-item Toronto Alexithymia Scale (TAS-20), Hospital Anxiety and Depression Scale (HADS), Self-Report Manic Inventory (SRMI), Apathy Evaluation Scale (AES), Unified Parkinson's Disease Rating Scale (UPDRS) activities of daily living, UPDRS motor examination and UPDRS complications (UPDRS-II/-III/-IV) and levodopa-equivalent daily dose (LEDD) pre-operatively and at 5-month follow-up. Outcome changes were tested with Wilcoxon signed-rank or paired t-test when parametric tests were applicable and corrected for multiple comparisons. The relationship between outcome changes was explored with bivariate correlations. Additionally, partial correlations between PDQ-8 and TAS-20 were computed controlling for HADS, SRMI and AES change scores. Predictor analyses for PDQ-8 improvement were calculated for all baseline parameters. RESULTS: The baseline prevalence of alexithymia was 17.9%. We observed significant beneficial effects of STN-DBS on PDQ-8, TAS-20, HADS, UPDRS-II, -III and -IV scores and significant LEDD reduction. The correlation between TAS-20 and PDQ-8 improvements remained significant after controlling for all other aforementioned outcomes. Predictor analyses for PDQ-8 improvement were significant for PDQ-8 and TAS-20. CONCLUSIONS: This is the first report of beneficial effects of STN-DBS on alexithymia. Alexithymia was significantly associated with QoL outcome independent of anxiety, depression, mania and apathy. Our study highlights the importance of alexithymia for holistic assessments of DBS outcomes.
Authors: Jan Bardon; Sandra Kurcova; Monika Chudackova; Pavel Otruba; David Krahulik; Martin Nevrly; Petr Kanovsky; Jana Zapletalova; Jan Valosek; Petr Hlustik; Miroslav Vastik; Marketa Vecerkova; Lenka Hvizdosova; Katerina Mensikova; Egon Kurca; Stefan Sivak Journal: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Date: 2020-12-07 Impact factor: 1.245
Authors: Thomas J C Zoon; Geeske van Rooijen; Georgina M F C Balm; Isidoor O Bergfeld; Joost G Daams; Paul Krack; Damiaan A J P Denys; Rob M A de Bie Journal: Mov Disord Date: 2020-12-16 Impact factor: 10.338
Authors: Stefanie T Jost; Veerle Visser-Vandewalle; Alexandra Rizos; Philipp A Loehrer; Monty Silverdale; Julian Evans; Michael Samuel; Jan Niklas Petry-Schmelzer; Anna Sauerbier; Alexandra Gronostay; Michael T Barbe; Gereon R Fink; Keyoumars Ashkan; Angelo Antonini; Pablo Martinez-Martin; K Ray Chaudhuri; Lars Timmermann; Haidar S Dafsari Journal: NPJ Parkinsons Dis Date: 2021-06-08
Authors: Stefanie T Jost; Lena Strobel; Alexandra Rizos; Philipp A Loehrer; Keyoumars Ashkan; Julian Evans; Franz Rosenkranz; Michael T Barbe; Gereon R Fink; Jeremy Franklin; Anna Sauerbier; Christopher Nimsky; Afsar Sattari; K Ray Chaudhuri; Angelo Antonini; Lars Timmermann; Pablo Martinez-Martin; Monty Silverdale; Elke Kalbe; Veerle Visser-Vandewalle; Haidar S Dafsari Journal: NPJ Parkinsons Dis Date: 2022-04-20
Authors: Haidar S Dafsari; K Ray-Chaudhuri; Keyoumars Ashkan; Lena Sachse; Picabo Mahlstedt; Monty Silverdale; Alexandra Rizos; Marian Strack; Stefanie T Jost; Paul Reker; Michael Samuel; Veerle Visser-Vandewalle; Julian Evans; Angelo Antonini; Pablo Martinez-Martin; Lars Timmermann Journal: J Neurol Date: 2020-03-09 Impact factor: 4.849
Authors: Anna Sauerbier; Philipp Loehrer; Stefanie T Jost; Shania Heil; Jan N Petry-Schmelzer; Johanna Herberg; Pia Bachon; Salima Aloui; Alexandra Gronostay; Lisa Klingelhoefer; J Carlos Baldermann; Daniel Huys; Christopher Nimsky; Michael T Barbe; Gereon R Fink; Pablo Martinez-Martin; K Ray Chaudhuri; Veerle Visser-Vandewalle; Lars Timmermann; Daniel Weintraub; Haidar S Dafsari Journal: J Neurol Neurosurg Psychiatry Date: 2021-09-11 Impact factor: 10.154